A Field Divided by Delivery
Genome Editing Has Reached a Critical Inflection Point
While the conversation once centred on whether CRISPR could work therapeutically, today's leading developers are focused on a different strategic question: should editing occur inside the patient's body or outside it?
The answer has significant implications for safety, scalability, manufacturing, clinical development, and commercial viability.
As more programs advance toward late-stage trials and commercialization, the distinction between in vivo and ex vivo editing is becoming one of the defining discussions in genetic medicine.
Understanding the Two Models
Ex vivo editing involves removing cells from a patient, genetically modifying them in a laboratory environment, and returning them following rigorous quality testing.
This approach offers greater control over editing outcomes and has already demonstrated clinical success in certain applications.
In vivo editing, by contrast, delivers editing machinery directly into the patient. The therapeutic is administered similarly to many conventional medicines, with editing occurring inside target tissues.
The potential advantages are clear:
- Simplified treatment logistics
- Larger patient populations
- Reduced manufacturing burden
- Broader commercial scalability
- Expansion into common diseases
Yet achieving efficient, tissue-specific delivery remains one of the biggest scientific challenges facing the industry.
Why Now?
The momentum behind in vivo editing has accelerated significantly over the last 18 months.
Clinical-stage companies are producing increasingly compelling human data, while advances in LNPs, AAV engineering, RNA delivery technologies, and novel delivery vehicles are expanding the number of tissues that can potentially be targeted.
At the same time, major pharmaceutical companies continue to invest in genome editing partnerships, reflecting growing confidence in the field's long-term clinical potential.
The question is no longer whether in vivo editing is possible. The question is whether it can outperform the established ex vivo paradigm.
The Companies Leading the Debate
Several leading developers are becoming synonymous with one side of the discussion.
Organizations such as Intellia Therapeutics, Metagenomi, and Scribe Therapeutics continue to push the boundaries of in vivo genome editing, developing new delivery systems and clinical strategies.
Meanwhile, companies including Beam Therapeutics have demonstrated the power of highly controlled editing workflows that provide extensive oversight of edited cells before patient administration.
The reality is that both approaches are generating important clinical value. However, each presents a different path toward commercialization.
Will One Approach Win?
Perhaps the better question is whether either approach needs to. Rare diseases, oncology applications, and cell therapy platforms may continue favouring ex vivo models where control and validation are paramount. Widespread genetic diseases, cardiovascular conditions, metabolic disorders, and larger patient populations may ultimately rely on scalable in vivo platforms.
Rather than a winner-takes-all outcome, the industry may be entering an era where therapeutic strategy depends on indication, biology, and delivery requirements.
Why This Conversation Belongs at the 7th Genome Editing Therapeutics Summit
One of the headline themes of the 7th Genome Editing Therapeutics Summit is the industry's transition from ex vivo manipulation toward increasingly sophisticated in vivo editing platforms.
Across three days, leaders from biotech, pharma, and academia will explore:
- Delivery innovation
- Next-generation LNPs
- Extrahepatic targeting strategies
- Regulatory considerations
- Clinical validation
- Product development acceleration
The discussion is no longer theoretical. It is shaping where investment flows, how companies build pipelines, and ultimately how patients gain access to transformative therapies.
Explore the Agenda
See exactly which delivery, manufacturing and regulatory sessions are relevant to your genome editing program.
Partner With Us
Put your solutions in front of the genome editing decision-makers actively looking for them.
Join Genome Editing Experts
Connect with the R&D, clinical and regulatory leaders driving genome editing therapeutics forward.